ArticleJournal of general internal medicine2026
Association Between Polypharmacy and Physical Function in Middle-aged Adults: Findings from the CARDIA Function Study.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPolypharmacy (≥ 5 medications) and potentially inappropriate medications (PIM; per Beers criteria) are common in midlife. Polypharmacy and PIM use are associated with poor physical function and adverse health outcomes in older age, but the associations of polypharmacy and PIM use with physical function in middle-age are poorly understood.
objectiveEstimate the associations of polypharmacy and PIM use with physical performance in middle-age.
designCross-sectional analysis of the Coronary Artery Risk Development in Young Adults (CARDIA) Function study.
participantsThe CARDIA prospective cohort study enrolled 5115 participants aged 18-30 in 1985-1986. We included participants with data on self-reported medication use who completed physical performance testing (gait speed, grip strength, 30-s chair stand, single-leg balance, 6-min walk test) at the year 35 in-person exam (2020-2022). MAIN MEASURES: The CARDIA Physical Performance (CAPP) score was calculated by assigning points to sex-specific quartiles for each test (0 = not attempted, 1-4 per quartile) and summing points across all five tests (0-20). We used multivariable linear regression to estimate the associations of polypharmacy and PIM use with CAPP score, adjusting for sociodemographics, multimorbidity, and physical activity history. For PIM use, a second model further adjusted for polypharmacy. KEY
resultsAmong 1842 participants (age 60 years ± 4; 49% female, 44% Black race), 29% had polypharmacy and 25% used ≥ 1 PIM. Estimated CAPP score was 1.24 points lower among participants with polypharmacy vs. no polypharmacy (95% confidence interval [95%CI] -1.58, -0.90; p < 0.001). Estimated CAPP score was 0.88 points lower among participants with PIMs vs. no PIMs after initial adjustment (95%CI -1.22, -0.54; p < 0.001). After adjusting for polypharmacy, PIM use was not associated with CAPP score.
conclusionsPolypharmacy is associated with lower physical function in middle-aged adults. Clinicians should consider systematically assessing physical function in middle-aged patients who have polypharmacy, to capture physical decline earlier in the lifespan.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.